Adjuvant activities of saponins from the root of Polygala senega L.

Canadian Journal of Physiology and Pharmacology

Volumn 85, Issue 11, 2007, Pages 1184-1194

  Katselis, Georgios S ^a,c   Estrada, Alberto ^b   Gorecki, Dennis K J ^a   Barl, Branka ^a,d  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b HEALTH CANADA   (Canada)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d Barl and Associates   (Canada)

Author keywords

Adjuvant; Immunological activity; Polygala senega; Quil A; Saponins; Senega root

Indexed keywords

ANTIGEN; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; OVALBUMIN; SAPONIN;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG FORMULATION; DRUG ISOLATION; DRUG MECHANISM; FEMALE; HEMOLYSIS; IMMUNIZATION; IMMUNOSTIMULATION; IN VITRO STUDY; MEDICINAL PLANT; MOUSE; NONHUMAN; PLANT ROOT; POLYGALA SENEGA; PRIORITY JOURNAL; QUILLAJA; QUILLAJA SAPONARIA; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; OVALBUMIN; PLANT ROOTS; POLYGALA; SAPONINS;

EID: 38849192318     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y07-109     Document Type: Article

References (42)

1. Audibert, F. 2003. Adjuvants for vaccines, a quest. Int. Immunopharmacol. 3: 1187-1193. doi:10.1016/S1567-5769(03)00011-0.
2. Barl, B., Loewen, D., and Svendsen, E. 1996. Polygala senega L. monograph. In Saskatchewan Herb Database, University of Saskatchewan, Saskatoon, Canada. pp. 105-110.
3. Bradley, P.R. 1992. Senega: Polygalae radix. In British herbal compendium. Vol. 1. A handbook of scientific information on widely used plant drugs. 1st ed. British Herbal Medicine Association, Dorset, UK. pp. 196-198.
4. Briggs, C.J. 1988. Senega snakeroot: a traditional Canadian herbal medicine. Can. Pharm. J. 121: 199-201.
5. Campbell, J.B. 1995. Saponins. In The theory and practical applications of adjuvants. Edited by D.E.S. Stewart-Tull. John Wiley & Sons Ltd., New York. pp. 95-127.
6. Campbell, J.B., and Peerbaye, Y. 1992. Saponin. Res. Immunol. 143: 526-530. doi:10.1016/0923-2494(92)80064-R.
7. Dalsgaard, K. 1974. Saponin adjuvants. Arch. Gesamte Virusforsch. 44: 243-254. doi:10.1007/BF01240612.
8. Edelman, R. 2001. An overview of adjuvant use. In Vaccine adjuvants: preparation methods and research protocols; methods in molecular medicine. Vol. 42. Edited by D. O'Hagan. Humana Press, Totowa, N.J. pp. 1-27.
9. Estrada, A., Van Kessel, A., Yun, C.H., and Li, B. 1998. Effect of endotoxin on cytokine production and cell dynamics in mice. Immunopharmacol. Immunotoxicol. 20: 217-231.
10. Estrada, A., Katselis, G.S., Laarveld, B., and Barl, B. 2000. Isolation and evaluation of immunological adjuvant activities of saponins from Polygala senega L. Comp. Immunol. Microbiol. Infect. Dis. 23: 27-43. doi:10.1016/S0147-9571(99)00020-X.
11. European Pharmacopoeia. 2002. Pertussis vaccine (acellular, component adsorbed). Monograph 1356, 4th ed. European Pharmacopoeia, Strasbourg, France.
12. Evans, T.G., McElrath, M.J., Matthews, T., Montefiori, D., Weinhold, K., Wolff, M., et al., NIAID AIDS Vaccine Evaluation Group. 2001. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine, 19: 2080-2091. doi:10.1016/S0264- 410X(00)00415-1.
13. Francis, G., Kerem, Z., Makkar, H.P.S., and Becker, K. 2002. The biological action of saponins in animal systems: a review. Br. J. Nutr. 88: 587-605. doi:10.1079/BJN2002725.
14. Gilbert, P.B., Chiu, Y.L., Allen, M., Lawrence, D.N., Chapdu, C., Israel, H., et al., NIAID HIV Vaccine Trials Network. 2003. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored phase I and II clinical trials. Vaccine, 21: 2933-2947. doi:10.1016/S0264-410X(03)00158-0.
15. Gupta, R.K., Relyveld, E.H., Lindblad, E.H., Bazzini, E.B., Ben-Efraim, S., and Gupta, C.K. 1993. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine, 11: 293-306. doi:10.1016/0264-410X(93)90190-9.
16. Hostettmann, K., and Marston, A. 1995. Chemistry and pharmacology of natural products: saponins. Edited by J.D. Phillipson, Cambridge University Press, New York.
17. 13C-NMR spectroscopy. Carbohydr. Res. 280: 1-14. doi:10.1016/0008-6215(95)00278-2.
18. Katselis, G.S. 1998. Development of an analytical protocol for quality evaluation of Polygala senega L. M.Sc. thesis, University of Saskatchewan, Saskatoon, Saskatchewan.
19. Katselis, G.S. 2006. Biologically active triterpene saponins from the root of the medicinal plant Polygala senega L. Ph.D. thesis, University of Saskatchewan, Saskatoon, Saskatchewan.
20. Kenkel, N.C., and Turcotte, C. 1996. The ethnobotany and economics of seneca snakeroot, Polygala senega L. Issues in the North, pp. 1-6.
21. Kensil, C.R., Patel, U., Lennick, M., and Marciani, D. 1991. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina Cortex. J. Immunol. 146: 431-437.
22. Kensil, C.R., Soltysic, S., Wheeler, D.A., and Wu, J.Y. 1996. Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria. In Saponins used in traditional and modern medicine: advances in experimental medicine and biology. Edited by G.R. Waller and K. Yamasaki. Plenum Press, New York. Adv. Exp. Med. Biol. 404: 165-172.
23. Kindscher, K. 1992. Medicinal plants of the prairie: an ethnobotanical guide. University of Kansas Press, Lawrence, Kan. pp. 164-168.
24. Lacaille-Dubois, M.A. 2000. Biologically and pharmacologically active saponins from plants: recent advances. In Proceedings of the Phytochemical Society of Europe. Vol. 45. Saponins in food, feedstuffs and medicinal plants. Edited by W. Oleszek and A. Marston. Kluwer Academic Publishers, London. pp. 205-218.
25. Liu, G., Anderson, C., Scaltreto, H., Barbon, J., and Kensil, C.R. 2002. QS-21 structure/function studies: effect of acylation on adjuvant activity. Vaccine, 20: 2808-2815. doi:10.1016/S0264-410X(02)00209-8.
26. Marciani, D.J., Pathak, A.K., Reynolds, R.C., Seitz, L., and May, R.D. 2001. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int. Immunopharmacol. 1: 813-818. doi:10.1016/S1567-5769(01)00016-9.
27. + T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites. Vaccine, 23: 2801-2812. doi:10.1016/j.vaccine.2004.10.044.
28. Nagai, T., Suzuki, Y., Kiyohara, H., Susa, E., Kato, T., Nagamine, T., et al. 2001. Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria-pertussis-tetanus vaccines. Vaccine, 19: 4824-4834. doi:10.1016/S0264-410X(01)00215-8.
29. Oda, K., Matsuda, H., Murakami, T., Katayama, S., Ohgitani, T., and Yoshikawa, M. 2000. Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants. Biol. Chem. 381: 67-74. doi:10.1515/BC.2000.009.
30. Santos, W.R., Bernardo, R.R., Pecanha, L.M., Palatnik, M., Parente, J.P., and de-Sousa, C.B. 1997. Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani. Vaccine, 15: 1024-1029. doi:10.1016/S0264-410X(96)00292-7.
31. Shoji, J., Kawanishi, S., and Tsukitani, Y. 1971a. On the structure of senegin-II of senegae radix. Chem. Pharm. Bull. (Tokyo), 19: 1740-1742.
32. Shoji, J., Kawanishi, S., and Tsukitani, Y. 1971b. Studies on the constituents of senegae radix. I. Isolation and qualitative analysis of the glycosides. Yakugaku Zasshi, 91: 198-202.
33. So, H.S., Yoon, H.S., Kwon, Y.S., and Cho, J.M. 1998. Quillaja saponin adjuvant and vaccine formulation containing same. United States Patent No. 5817314.
34. Soltysik, S., Wu, J.Y., Recchia, J., Wheeler, D.A., Newman, M.J., Coughlin, R.T., and Kensil, C.R. 1995. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine, 13: 1403-1410. doi:10.1016/0264-410X(95) 00077-E.
35. Sun, H.X., Ye, Y.P., Pan, H.J., and Pan, Y.J. 2004. Adjuvant effect of Panax notoginseng saponins on the immune responses to ovalbumin in mice. Vaccine, 22: 3882-3889. doi:10.1016/j.vaccine.2004.04.012.
36. Takechi, M., and Tanaka, Y. 1995. Haemolytic time course differences between steroid and triterpenoid saponins. Planta Med. 61: 76-77. doi:10.1055/s-2006-958006.
37. van Setten, D.C., and van de Werken, G. 1996. Molecular structures of saponins from Quillaja saponaria Molina. In Saponins used in traditional and modern medicine. Edited by G.R. Waller and K. Yamasaki. Adv. Exp. Med. Biol. 404: 185-193.
38. Vogel, F.R. 2000. Improving vaccine performance with adjuvants. Clin. Infect. Dis. 30: S266-S270. doi:10.1086/313883.
39. Wagner, H., Bladt, S., and Zgainski, E.M. 1984. Plant drug analysis: a thin layer chromatography atlas. Translation of the German edition 'Drogenanalyse' by T.A. Scott, Springer-Verlag, Berlin. pp. 225-245.
40. Yoshikawa, M., Murakami, T., Ueno, T., Kadoya, M., Matsuda, H., Yamahara, J., and Murakami, N. 1995a. E-Senegasaponins a and b, Z-Senegasaponins a and b, Z-senegins II and III, new type inhibitors of ethanol absorption in rats from senegae radix, the roots of Polygala senega L. var. latifolia Torry et Gray. Chem. Pharm. Bull. (Tokyo), 43: 350-352.
41. Yoshikawa, M., Murakami, T., Ueno, T., Kadoya, M., Matsuda, H., Yamahara, J., and Murakami, N. 1995b. Bioactive saponins and glycosides. I. Senegae radix. (1): E-Senegasaponins a and b and Z-Senegasaponins a and b, their inhibitory effect on alcohol absorption and hypoglycemic activity. Chem. Pharm. Bull. (Tokyo), 43: 2115-2122.
42. Yoshikawa, M., Murakami, T., Matsuda, H., Ueno, T., Kadoya, M., Yamahara, J., and Murakami, N. 1996. Bioactive saponins and glycosides. II. Senegae radix. (2): chemical structures, hypoglycemic activity, and ethanol absorption-inhibitory effect of E-Senegasaponin c, Z-Senegasaponin c, and Z-Senegins II, III, and IV. Chem. Pharm. Bull. (Tokyo), 44: 1305-1313.